BMS spends $200m to buy bluebird out of CAR-T payments 12-May-2020 By Ben Hargreaves With the partners’ CAR-T therapy under review by the FDA, BMS chooses to purchase bluebird’s royalty rights and take control of ex-US manufacturing.
Dyno launches with gene therapy partnership alongside Novartis 11-May-2020 By Ben Hargreaves The biotech emerges from stealth mode with two partnerships potentially worth in excess of $2bn.
AskBio buys BrainVectis for early-stage gene therapies 27-Apr-2020 By Ben Hargreaves AskBio acquires gene therapy biotech working on treatments for neurodegenerative disorders.
Mogrify and Sangamo in license agreement for ‘off-the-shelf’ CAR-Treg 23-Apr-2020 By Ben Hargreaves Sangamo plans to utilize Mogrify’s cell conversion technology to develop CAR-Treg cell therapies.
MilliporeSigma set to build $100m facility for viral and gene therapies 23-Apr-2020 By Ben Hargreaves The facility will be the company’s second facility in Carlsbad specifically for its BioReliance viral and gene therapy service.
How is the supply chain for immunotherapies impacted by COVID-19? 15-Apr-2020 By Ben Hargreaves COO of Dendreon explains how ‘every part’ of the supply chain for the company’s lead product has been affected by the novel coronavirus.
Takeda taps Evotec for gene therapy discovery 14-Apr-2020 By Ben Hargreaves Looking to expand its pipeline of gene therapies, Takeda announces a long-term research partnership with Evotec.
ElevateBio closes $170m Series B financing round 09-Apr-2020 By Ben Hargreaves The accelerator for cell and gene therapy startups reveals the closure of its second financing round and how the funds will be used.
Symbiosis doubles footprint of UK biologics site 09-Apr-2020 By Ben Hargreaves The CMO expands its Sterling site to add new office space, as well as expanding manufacturing space and supporting services.
Hired and Retired: Management moves in a time of crisis 08-Apr-2020 By Ben Hargreaves As the pandemic continues to rumble on, biopharma companies have been reshuffling the pack on their executive boards.
J&J signs deal with Fate for off-the-shelf immunotherapies 06-Apr-2020 By Ben Hargreaves Fate Therapeutics and J&J will collaborate to progress candidates against four tumor-associated antigens.
Daiichi pays $225m to access gene therapy production platform 06-Apr-2020 By Ben Hargreaves Daiichi partners with Ultragenyx to utilize its HeLa producer cell line platform for commercial-scale gene therapy production.
Avectas partners with Vycellix to speed cell therapy production 31-Mar-2020 By Ben Hargreaves The partners will combine expertise to progress the novel RNA immunomodulator, VY-M.
Novartis’ gene therapy takes additional step towards EU approval 30-Mar-2020 By Ben Hargreaves Zolgensma has received a recommendation for approval despite running into problems recently, including manufacturing questions and data integrity issues.
Thermo Fisher to invest $475m into biopharma in 2020 25-Mar-2020 By Ben Hargreaves Continuing a trend among larger CDMOs, Thermo Fisher reveals scale of investment into biopharma business and further focus on cell and gene therapy.
